J&J says troubled plant passes audit; Merck expands Russian manufacturing with CMO;

> A new study found that India's generics exports are growing at nearly 30% per year. Release

> Merck ($MRK) will have its Russian CMO Akrikhin add 5 more products to the 6 it is already manufacturing for the company there. Report

> According to the Stericycle ExpertRecall index, the number of units recalled in the last quarter was up 32%, and 5 companies accounted for 65% of recalled units. Report (pdf)

> The FDA is reminding healthcare providers not to use sterile products manufactured by compounding pharmacy NuVision Pharmacy of Dallas, Texas, due to concerns they may be contaminated. Notice

> CSL, the Australian blood product specialist, has completed a new plant in Victoria state that in 2016 will begin producing its intravenous immunoglobulin treatment Privigen. Story

> MIT chemical engineers say that pharmaceutical companies might be able to use arrays of billions of nanoscale sensors to help produce drugs. Story

> Covidien ($COV) has recalled 14 lots of its Monoject prefilled flush syringes sold from the U.S. and Bermuda because they contain nonsterilized water that could cause infections. Article

And Finally... Johnson & Johnson ($JNJ) says its troubled OTC plant in Fort Washington, PA, has passed an audit by its outside consultant. Report